Sign up
Pharma Capital

Amryt Pharma making major advances after successful Lojuxta trial

Dr Helen Phillips, head of medical affairs at Amryt Pharma PLC (LON:AMYT) discusses with Proactive a recently published long-term study of the drug Lojuxta which further confirmed its efficacy in lowering high cholesterol levels resulting from a rare genetic disorder.

The assessment of Lojuxta, also known as lomitapide, followed the progress of patients with Homozygous Familial Hypercholesterolaemia (HoFH).


View full AMYT profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.